Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

Nikoletta Lendvai; Ioanna Tsakos; Sean M. Devlin; Wendy L. Schaffer; Hani Hassoun; Alexander M. Lesokhin; Heather Landau; Neha Korde; Sham Mailankody; Eric Smith; David J. Chung; Guenther Koehne; Gunjan L. Shah; Aeri Alexander; Minal Patel; Andrea Ballagi; Ida Grundberg; Sergio A. Giralt; Ola Landgren

Article

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

Leukemia and Lymphoma

DOI: 10.1080/10428194.2017.1403020

17Citations

27Readers

Get full text

Cite

CITATION STYLE

APA

Lendvai, N., Tsakos, I., Devlin, S. M., Schaffer, W. L., Hassoun, H., Lesokhin, A. M., … Landgren, O. (2018, August 3). Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia and Lymphoma. Taylor and Francis Ltd. https://doi.org/10.1080/10428194.2017.1403020

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

Cite

Register to see more suggestions